Come up with a name for your new list and we'll add to it:
Innocrin Pharmaceuticals raised a round of funding on , . Investors include
Astellas Venture Management.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally…